Daily Stock Analysis, ATNM, Actinium Pharmaceuticals Inc, priceseries

Actinium Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.65
Close
0.67
High
0.69
Low
0.64
Previous Close
0.65
Daily Price Gain
0.02
YTD High
1.72
YTD High Date
Feb 9, 2017
YTD Low
0.54
YTD Low Date
Aug 23, 2017
YTD Price Change
-0.24
YTD Gain
-26.47%
52 Week High
1.72
52 Week High Date
Feb 9, 2017
52 Week Low
0.54
52 Week Low Date
Aug 23, 2017
52 Week Price Change
-0.35
52 Week Gain
-34.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 17. 2015
3.03
Mar 18. 2015
3.19
1 Trading Days
5.28%
Link
LONG
May 20. 2015
2.70
Jun 1. 2015
3.30
7 Trading Days
22.17%
Link
LONG
Sep 1. 2015
2.11
Sep 16. 2015
2.22
10 Trading Days
5.37%
Link
LONG
Dec 23. 2015
2.49
Jan 6. 2016
2.82
8 Trading Days
13.13%
Link
LONG
Nov 9. 2016
0.96
Nov 21. 2016
1.01
8 Trading Days
5.68%
Link
LONG
Feb 7. 2017
1.26
Feb 13. 2017
1.33
4 Trading Days
5.75%
Link
Company Information
Stock Symbol
ATNM
Exchange
NYSE MKT
Company URL
http://http://www.actiniumpharma.com
Company Phone
646-677-3875
CEO
Kaushik J. Dave
Headquarters
New York
Business Address
275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001388320
About

Actinium Pharmaceutical, Inc., a biopharmaceutical company, engages in developing treatments for cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar tec...

Description

Actinium Pharmaceutical, Inc., a biopharmaceutical company, engages in developing treatments for cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its product candidates include Actimab-A, an antibody-drug construct comprising monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225 that is in multicenter Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct comprising the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, which is in preparation for a pivotal Phase III multicenter clinical trial for use in bone marrow conditioning for hematopoietic stem cells transplantation in relapsed and refractory AML patients. Actinium Pharmaceutical, Inc. was founded in 2000 and is headquartered in New York, New York.